Abstract:Early insulin therapy is capable to achieve glycemic control and restore β-cell function in newly diagnosed type 2 diabetes (T2D), but its effect on cardiovascular outcomes in these patients remains unclear. In this nationwide real-world study, we analyzed electronic health record data from 19 medical centers across China between 1 January 2000, and 26 May 2022. We included 5424 eligible patients (mean age 56 years, 2176 women/3248 men) who were diagnosed T2D within six months and did not have prior cardiovascular disease. Multivariable Cox regression models were used to estimate the associations of early insulin therapy (defined as the first-line therapy for at least two weeks in newly diagnosed T2D patients) with the incidence of major cardiovascular events including coronary heart disease (CHD), stroke, and hospitalization for heart failure (HF). During 17,158 persons years of observation, we documented 834 incident CHD cases, 719 stroke cases, and 230 hospitalized cases for HF. Newly diagnosed T2D patients who received early insulin therapy, compared with those who did not receive such treatment, had 31% lower risk of incident stroke, and 28% lower risk of hospitalization for HF. No significant difference in the risk of CHD was observed. We found similar results when repeating the aforesaid analysis in a propensity-score matched population of 4578 patients and with inverse probability of treatment weighting models. These findings suggest that early insulin therapy in newly diagnosed T2D may have cardiovascular benefits by reducing the risk of incident stroke and hospitalization for HF.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: the impact of early insulin treatment on the incidence of cardiovascular events in newly diagnosed type 2 diabetes (T2D) patients. Specifically, the study aims to evaluate whether early insulin treatment can reduce the risks of coronary heart disease (CHD), stroke, and hospitalization due to heart failure (HF). ### Research Background Type 2 diabetes (T2D) is a known risk factor for the morbidity and mortality of cardiovascular diseases. The results of cardiovascular outcome trials in the past decade have shown that different hypoglycemic regimens have different impacts on cardiovascular events. Some drugs, such as glibenclamide and glipizide, increase the risks of cardiovascular and cerebrovascular events, while sodium - glucose cotransporter 2 inhibitors (SGLT2i) and glucagon - like peptide - 1 receptor agonists (GLP - 1 RA) show beneficial effects in reducing major cardiovascular events. Therefore, clinical guidelines emphasize the importance of reducing cardiovascular events in addition to lowering blood glucose levels when choosing drugs for the management of T2D. ### Research Objectives This study aims to evaluate the actual effects of early insulin treatment on the incidence of major cardiovascular events (including coronary heart disease, stroke, and hospitalization due to heart failure) in newly diagnosed type 2 diabetes patients based on the data of the nationwide collaborative network in China. ### Main Findings - **Stroke**: The risk of stroke in patients receiving early insulin treatment was 31% lower than that in patients not receiving this treatment (HR 0.69, 95% CI 0.58 – 0.81). - **Hospitalization due to heart failure**: The risk of hospitalization due to heart failure in patients receiving early insulin treatment was 28% lower than that in patients not receiving this treatment (HR 0.72, 95% CI 0.53 – 0.99). - **Coronary heart disease**: No significant impact of early insulin treatment on the risk of coronary heart disease was observed (HR 1.08, 95% CI 0.92 – 1.28). ### Sensitivity Analysis - **Propensity score matching**: In the 1:1 propensity - score - matched population, early insulin treatment was associated with a 31% reduction in stroke risk (HR 0.69, 95% CI 0.56 – 0.85) and a 36% reduction in the risk of hospitalization due to heart failure (HR 0.64, 95% CI 0.45 – 0.92), but had no significant association with the risk of coronary heart disease (HR 1.10, 95% CI 0.91 – 1.32). - **Inverse probability weighting**: In the inverse probability - weighted model, early insulin treatment was associated with a 31% reduction in stroke risk (HR 0.69, 95% CI 0.58 – 0.82) and a 33% reduction in the risk of hospitalization due to heart failure (HR 0.67, 95% CI 0.47 – 0.95), but had no significant difference in the risk of coronary heart disease (HR 1.12, 95% CI 0.94 – 1.33). ### Discussion This is the first study to show that early insulin treatment significantly reduces cardiovascular events in newly diagnosed type 2 diabetes patients. Early insulin treatment not only helps to restore β - cell function and promote long - term glycemic remission, but may also reduce cardiovascular risks by improving low - grade inflammation and endothelial function. These findings are consistent with the results of previous studies such as UKPDS and VADT, indicating that early intensive glycemic control can reduce the risk of cardiovascular events. ### Conclusion Early insulin treatment has potential cardiovascular benefits in newly diagnosed type 2 diabetes patients, especially in reducing the risks of stroke and hospitalization due to heart failure. This finding provides an important scientific basis for further exploring the application of early insulin treatment in the management of type 2 diabetes.

Real-world effectiveness of early insulin therapy on the incidence of cardiovascular events in newly diagnosed type 2 diabetes

Effect of Intensive Multifactorial Treatment on the Intima-Media Thickness of Large Arteries in Patients with New-Onset Type 2 Diabetes Mellitus

436-P: Stringent Glycemic Control and Long-Term Macrovascular Outcomes in People with Type 2 Diabetes in China—A Retrospective Study

Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study

Comparisons of clinical outcomes between newly diagnosed early- and late-onset T2DM: a real-world study from the Shanghai Hospital Link Database

Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims

Treating Type 2 Diabetes With Early, Intensive, Multimodal Pharmacotherapy: Real-World Evidence From an International Collaborative Database

PDG8 EFFICACY OF PHARMACOLOGICAL MONOTHERAPIES FOR TYPE 2 DIABETES IN CHINA

Effect of Intensive Insulin Therapy on Β-Cell Function and Glycaemic Control in Patients with Newly Diagnosed Type 2 Diabetes: a Multicentre Randomised Parallel-Group Trial

The Long-Term Effectiveness of Metabolic Control on Cardiovascular Disease in Patients with Diabetes in a Real-World Health Care Setting - A Prospective Diabetes Management Study.

Glycemic Control Rate of T2DM Outpatients in China: A Multi-Center Survey

Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia

Long-Term Effects Intensive Medical Therapy on the Development and Progression of Subclinical Atherosclerosis and the Metabolic Syndrome in Chinese Patients with Type 2 Diabetes Mellitus

The Risk Factors of Glycemic Control, Blood Pressure Control, Lipid Control in Chinese Patients with Newly Diagnosed Type 2 Diabetes _ A Nationwide Prospective Cohort Study.

The Long-Term Cardiovascular Effects of Metformin on Patients with Newly Diagnosed Type 2 Diabetes

Ten-year clinical characteristics of patients with early-onset type 2 diabetes: A single-center experience in China

Early Therapy for Type 2 Diabetes in China.

Effects of basal and premixed insulin on glycemic control in type 2 diabetes patients based on multicenter prospective real-world data

Association of age at diagnosis of type 2 diabetes mellitus with the risks of the morbidity of cardiovascular disease, cancer and all-cause mortality: Evidence from a real-world study with a large population-based cohort study

Evaluation of Effectiveness of Treatment Paradigm for Newly Diagnosed Type 2 Diabetes Patients in Chin: A Nationwide Prospective Cohort Study

Effects on All-Cause Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes by Comparing Insulin With Oral Hypoglycemic Agent Therapy: A Meta-Analysis of Randomized Controlled Trials.